3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
39
Neoplasm Metastasis
5
Metastatic Castration-resistant Prostate Cancer
3
Triple Negative Breast Neoplasms
2
Breast Neoplasms
2
Urogenital Neoplasms
1
Thrombocytosis
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
enzalutamide
6
Abiraterone Acetate
5
abiraterone
2
Prednisone
2
pembrolizumab
1
darolutamide
1
cabazitaxel
1
apalutamide
1
TVB-2640
1
Standard of Care
1
Radiosurgery
1
Pluvicto
1
Photons
1
Omeprazole
1
Nivolumab
1
Ipilimumab
1
Gonadotropin-Releasing Hormone
1
Exome Sequencing
1
Drug Therapy
1
CTLA-4 Antigen
1
Artificial Intelligence
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostatic Neoplasms, Castration-Resistant
×
darolutamide
×
Clear all
NCT06276465
2024-12-20
PEACE8
UNICANCER
Phase 3
Recruiting
336 enrolled